172 related articles for article (PubMed ID: 27861291)
1. Preclinical Testing of Antihuman CD28 Fab' Antibody in a Novel Nonhuman Primate Small Animal Rodent Model of Xenogenic Graft-Versus-Host Disease.
Hippen KL; Watkins B; Tkachev V; Lemire AM; Lehnen C; Riddle MJ; Singh K; Panoskaltsis-Mortari A; Vanhove B; Tolar J; Kean LS; Blazar BR
Transplantation; 2016 Dec; 100(12):2630-2639. PubMed ID: 27861291
[TBL] [Abstract][Full Text] [Related]
2. CD28 blockade controls T cell activation to prevent graft-versus-host disease in primates.
Watkins BK; Tkachev V; Furlan SN; Hunt DJ; Betz K; Yu A; Brown M; Poirier N; Zheng HB; Taraseviciute A; Colonna L; Mary C; Blancho G; Soulillou JP; Panoskaltsis-Mortari A; Sharma P; Garcia A; Strobert E; Hamby K; Garrett A; Deane T; Blazar BR; Vanhove B; Kean LS
J Clin Invest; 2018 Aug; 128(9):3991-4007. PubMed ID: 30102255
[TBL] [Abstract][Full Text] [Related]
3. Effective treatment against severe graft-versus-host disease with allele-specific anti-HLA monoclonal antibody in a humanized mouse model.
Nakauchi Y; Yamazaki S; Napier SC; Usui J; Ota Y; Takahashi S; Watanabe N; Nakauchi H
Exp Hematol; 2015 Feb; 43(2):79-88.e1-4. PubMed ID: 25448490
[TBL] [Abstract][Full Text] [Related]
4. Phytohemagglutinin-activated human T cells induce lethal graft-versus-host disease in cyclophosphamide and anti-CD122 conditioned NOD/SCID mice.
Hu Y; Gu Y; Cui Q; Fu H; Sheng L; Wu K; Liu L; Fu S; Yu X; Huang H
Ann Hematol; 2012 Nov; 91(11):1803-12. PubMed ID: 22699803
[TBL] [Abstract][Full Text] [Related]
5. Preclinical efficacy and immunological safety of FR104, an antagonist anti-CD28 monovalent Fab' antibody.
Poirier N; Mary C; Dilek N; Hervouet J; Minault D; Blancho G; Vanhove B
Am J Transplant; 2012 Oct; 12(10):2630-40. PubMed ID: 22759318
[TBL] [Abstract][Full Text] [Related]
6. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
7. Highly sensitive model for xenogenic GVHD using severe immunodeficient NOG mice.
Ito R; Katano I; Kawai K; Hirata H; Ogura T; Kamisako T; Eto T; Ito M
Transplantation; 2009 Jun; 87(11):1654-8. PubMed ID: 19502956
[TBL] [Abstract][Full Text] [Related]
8. Modeling Human Graft-Versus-Host Disease in Immunocompromised Mice.
Norelli M; Camisa B; Bondanza A
Methods Mol Biol; 2016; 1393():127-32. PubMed ID: 27033222
[TBL] [Abstract][Full Text] [Related]
9. Prevention of lethal acute GVHD with an agonistic CD28 antibody and rapamycin.
Albert MH; Yu XZ; Martin PJ; Anasetti C
Blood; 2005 Feb; 105(3):1355-61. PubMed ID: 15459004
[TBL] [Abstract][Full Text] [Related]
10. Cytotoxic T lymphocyte antigen-4 regulates development of xenogenic graft versus host disease in mice via modulation of host immune responses induced by changes in human T cell engraftment and gene expression.
Gao C; Gardner D; Theobalds MC; Hitchcock S; Deutsch H; Amuzie C; Cesaroni M; Sargsyan D; Rao TS; Malaviya R
Clin Exp Immunol; 2021 Dec; 206(3):422-438. PubMed ID: 34487545
[TBL] [Abstract][Full Text] [Related]
11. FR104, an antagonist anti-CD28 monovalent fab' antibody, prevents alloimmunization and allows calcineurin inhibitor minimization in nonhuman primate renal allograft.
Poirier N; Dilek N; Mary C; Ville S; Coulon F; Branchereau J; Tillou X; Charpy V; Pengam S; Nerriere-Daguin V; Hervouet J; Minault D; Le Bas-Bernardet S; Renaudin K; Vanhove B; Blancho G
Am J Transplant; 2015 Jan; 15(1):88-100. PubMed ID: 25488654
[TBL] [Abstract][Full Text] [Related]
12. T lymphocytes determine the development of xeno GVHD and of human hemopoiesis in NOD/SCID mice following human umbilical cord blood transplantation.
Verlinden SF; Mulder AH; de Leeuw JP; van Bekkum DW
Stem Cells; 1998; 16 Suppl 1():205-17. PubMed ID: 11012164
[TBL] [Abstract][Full Text] [Related]
13. Preemptive administration of human αβ T cell receptor-targeting monoclonal antibody GZ-αβTCR potently abrogates aggressive graft-versus-host disease in vivo.
Blank G; Welker C; Sipos B; Sonntag K; Müller F; Eckert F; Seitz C; Nadalin S; LaCorcia G; Königsrainer A; Snell D; Handgretinger R; Schilbach K
Ann Hematol; 2015 Nov; 94(11):1907-19. PubMed ID: 26264693
[TBL] [Abstract][Full Text] [Related]
14. Preclinical models of acute and chronic graft-versus-host disease: how predictive are they for a successful clinical translation?
Zeiser R; Blazar BR
Blood; 2016 Jun; 127(25):3117-26. PubMed ID: 26994149
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic efficacy of cord blood-derived mesenchymal stromal cells for the prevention of acute graft-versus-host disease in a xenogenic mouse model.
Gregoire-Gauthier J; Selleri S; Fontaine F; Dieng MM; Patey N; Despars G; Beauséjour CM; Haddad E
Stem Cells Dev; 2012 Jul; 21(10):1616-26. PubMed ID: 21910645
[TBL] [Abstract][Full Text] [Related]
16. [Establishment of an xenogeneic acute graft-versus-host disease model in NOD/SCID mice by engraftment of G-CSF mobilized human mononuclear cells].
Gao L; Wang JM; Xie LN; Zhou H; Qiu HY
Zhonghua Xue Ye Xue Za Zhi; 2008 Feb; 29(2):87-91. PubMed ID: 18681307
[TBL] [Abstract][Full Text] [Related]
17. GVHD after haploidentical transplantation: a novel, MHC-defined rhesus macaque model identifies CD28- CD8+ T cells as a reservoir of breakthrough T-cell proliferation during costimulation blockade and sirolimus-based immunosuppression.
Miller WP; Srinivasan S; Panoskaltsis-Mortari A; Singh K; Sen S; Hamby K; Deane T; Stempora L; Beus J; Turner A; Wheeler C; Anderson DC; Sharma P; Garcia A; Strobert E; Elder E; Crocker I; Crenshaw T; Penedo MC; Ward T; Song M; Horan J; Larsen CP; Blazar BR; Kean LS
Blood; 2010 Dec; 116(24):5403-18. PubMed ID: 20833977
[TBL] [Abstract][Full Text] [Related]
18. Role of Natural Killer Cells in Intravenous Immunoglobulin-Induced Graft-versus-Host Disease Inhibition in NOD/LtSz-scidIL2rg(-/-) (NSG) Mice.
Gregoire-Gauthier J; Fontaine F; Benchimol L; Nicoletti S; Selleri S; Dieng MM; Haddad E
Biol Blood Marrow Transplant; 2015 May; 21(5):821-8. PubMed ID: 25596424
[TBL] [Abstract][Full Text] [Related]
19. Insights into mechanisms of graft-versus-host disease through humanised mouse models.
Elhage A; Sligar C; Cuthbertson P; Watson D; Sluyter R
Biosci Rep; 2022 Sep; 42(9):. PubMed ID: 35993192
[TBL] [Abstract][Full Text] [Related]
20. Mesenchymal stem cells of cord blood origin are effective at preventing but not treating graft-versus-host disease.
Tisato V; Naresh K; Girdlestone J; Navarrete C; Dazzi F
Leukemia; 2007 Sep; 21(9):1992-9. PubMed ID: 17625609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
